Profile data is unavailable for this security.
About the company
Inovio Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines pipeline include INO-3107 for HPV-related recurrent respiratory papillomatosis (RRP); INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, or OPSCC; VGX-3100 for the treatment of Anal or Perianal HSIL; INO-5401 for the treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Treatment of Glioblastoma Multiforme (GBM). Its lead candidate is INO-3107 for the treatment of RRP, a rare and debilitating disease of the respiratory tract caused by HPV infection. Its DNA medicines platform consists of DNA plasmids and its CELLECTRA devices, which are used to deliver the DNA plasmids into the cell. Its CELLECTRA device portfolio consists of two models.
- Revenue in USD (TTM)203.41k
- Net income in USD-112.88m
- Incorporated2001
- Employees122.00
- LocationInovio Pharmaceuticals Inc6769 Mesa Ridge Rd.SAN DIEGO 92121United StatesUSA
- Phone+1 (858) 410-3134
- Fax+1 (858) 404-1392
- Websitehttps://www.inovio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anixa Biosciences Inc | 0.00 | -12.36m | 98.47m | 4.00 | -- | 4.52 | -- | -- | -0.3906 | -0.3906 | 0.00 | 0.6772 | 0.00 | -- | -- | 0.00 | -50.54 | -59.69 | -52.50 | -62.61 | -- | -- | -- | -6,040.10 | -- | -- | 0.00 | -- | -- | -28.36 | 27.83 | -- | -- | -- |
| Milestone Pharmaceuticals Inc | 0.00 | -42.77m | 98.55m | 47.00 | -- | 4.11 | -- | -- | -0.8066 | -0.8066 | 0.00 | 0.4503 | 0.00 | -- | -- | 0.00 | -50.37 | -48.44 | -54.67 | -51.56 | -- | -- | -- | -1,267.25 | -- | -- | 0.6859 | -- | -80.00 | -- | -2.22 | -- | 86.23 | -- |
| Leap Therapeutics Inc | 0.00 | -64.82m | 98.72m | 54.00 | -- | 2.02 | -- | -- | -1.93 | -1.93 | 0.00 | 1.28 | 0.00 | -- | -- | 0.00 | -87.23 | -80.06 | -106.79 | -95.03 | -- | -- | -- | -7,900.37 | -- | -- | 0.00 | -- | -- | -- | -49.12 | -- | -- | -- |
| Fractyl Health Inc | 97.00k | -68.97m | 98.73m | 102.00 | -- | 1.97 | -- | 1,017.84 | -1.43 | -1.43 | 0.002 | 1.05 | 0.0011 | 0.698 | 8.08 | 950.98 | -68.48 | -- | -78.83 | -- | 46.39 | -- | -64,849.48 | -- | 5.57 | -- | 0.376 | -- | -- | -- | -48.15 | -- | -- | -- |
| Immunic Inc | 0.00 | -96.90m | 99.99m | 77.00 | -- | 2.43 | -- | -- | -1.24 | -1.24 | 0.00 | 0.4576 | 0.00 | -- | -- | 0.00 | -147.12 | -72.09 | -213.91 | -80.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 22.25 | -- | -10.97 | -- |
| Avalo Therapeutics Inc | 820.00k | -8.14m | 100.30m | 19.00 | -- | 4.43 | -- | 122.32 | -10.96 | -10.96 | 0.1976 | 2.35 | 0.0128 | -- | 0.6467 | 43,157.89 | -12.46 | -99.64 | -26.07 | -154.42 | 182.20 | 84.69 | -970.49 | -613.58 | -- | -6.69 | 0.00 | -- | -89.34 | -22.83 | 24.28 | -- | -22.48 | -- |
| Coya Therapeutics Inc | 9.55m | -10.70m | 101.58m | 8.00 | -- | 2.89 | -- | 10.63 | -0.6928 | -0.6928 | 0.687 | 2.10 | 0.4027 | -- | -- | 1,194,290.00 | -45.10 | -- | -49.39 | -- | -- | -- | -111.98 | -- | -- | -- | 0.00 | -- | -- | -- | 34.77 | -- | -- | -- |
| Monopar Therapeutics Inc | 0.00 | -6.47m | 104.03m | 10.00 | -- | 14.05 | -- | -- | -1.99 | -1.99 | 0.00 | 1.40 | 0.00 | -- | -- | 0.00 | -88.32 | -54.07 | -112.04 | -60.60 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 20.10 | -- | -- | -- |
| Inovio Pharmaceuticals Inc | 203.41k | -112.88m | 105.41m | 122.00 | -- | 1.44 | -- | 518.24 | -4.49 | -4.49 | 0.008 | 2.82 | 0.0014 | -- | 0.2184 | 1,667.30 | -75.21 | -59.52 | -96.91 | -71.29 | -- | -- | -55,491.91 | -4,097.36 | -- | -- | 0.00 | -- | -91.89 | -51.33 | 51.71 | -- | -31.22 | -- |
| Century Therapeutics Inc | 2.69m | -129.89m | 105.44m | 152.00 | -- | 0.5358 | -- | 39.27 | -1.86 | -1.86 | 0.0372 | 2.31 | 0.0068 | -- | -- | 17,664.47 | -33.04 | -- | -34.83 | -- | -- | -- | -4,837.73 | -- | -- | -- | 0.00 | -- | -57.01 | -- | -4.38 | -- | -- | -- |
| INmune Bio Inc | 42.00k | -41.27m | 105.54m | 11.00 | -- | 2.73 | -- | 2,512.88 | -2.18 | -2.18 | 0.0022 | 1.74 | 0.0007 | -- | 0.0228 | 3,818.18 | -71.48 | -37.82 | -94.55 | -41.86 | -- | -- | -98,266.66 | -14,901.03 | -- | -34.08 | 0.0606 | -- | -58.56 | -- | -9.92 | -- | -- | -- |
| Tiziana Life Sciences Ltd - ADR | 0.00 | -17.69m | 107.34m | 9.00 | -- | 18.06 | -- | -- | -0.1726 | -0.1726 | 0.00 | 0.0537 | 0.00 | -- | -- | 0.00 | -91.52 | -58.16 | -138.98 | -75.36 | -- | -- | -- | -- | -- | -- | 0.0427 | -- | -- | -- | -14.90 | -- | -- | -- |
| Rani Therapeutics Holdings Inc | 0.00 | -28.17m | 109.36m | 140.00 | -- | 35.26 | -- | -- | -1.06 | -1.06 | 0.00 | 0.0579 | 0.00 | -- | -- | 0.00 | -96.37 | -- | -165.17 | -- | -- | -- | -- | -- | -- | -16.57 | 0.8306 | -- | -- | -- | -11.06 | -- | -- | -- |
| Alto Neuroscience Inc | 0.00 | -57.45m | 110.26m | 88.00 | -- | 0.6683 | -- | -- | -2.42 | -2.42 | 0.00 | 6.12 | 0.00 | -- | -- | 0.00 | -46.93 | -- | -51.10 | -- | -- | -- | -- | -- | -- | -- | 0.0649 | -- | -- | -- | -31.02 | -- | -- | -- |
| Context Therapeutics Inc | 0.00 | -30.15m | 112.50m | 5.00 | -- | 1.34 | -- | -- | -0.9117 | -0.9117 | 0.00 | 1.12 | 0.00 | -- | -- | 0.00 | -55.16 | -- | -58.90 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -61.53 | -- | -- | -- |
Data as of Nov 22 2024. Currency figures normalised to Inovio Pharmaceuticals Inc's reporting currency: US Dollar USD
28.19%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Deep Track Capital LPas of 30 Sep 2024 | 1.80m | 6.95% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 1.78m | 6.84% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 1.75m | 6.72% |
| Geode Capital Management LLCas of 30 Sep 2024 | 621.63k | 2.39% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 490.66k | 1.89% |
| Renaissance Technologies LLCas of 30 Sep 2024 | 331.07k | 1.28% |
| Northern Trust Investments, Inc.(Investment Management)as of 30 Sep 2024 | 205.79k | 0.79% |
| GMT Capital Corp.as of 30 Sep 2024 | 126.12k | 0.49% |
| Dimensional Fund Advisors LPas of 30 Sep 2024 | 118.21k | 0.46% |
| Susquehanna Investment Group LLCas of 30 Jun 2024 | 99.99k | 0.39% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
